

20 July 2010

Dr YEUNG Chiu-fat President Hong Kong Doctors' Union

Ms Iris CHANG President The Practising Pharmacists Association of Hong Kong

Mr K P TSANG Chairman Retina Hong Kong

Dear Dr YEUNG, Ms CHANG and Mr TSANG,

電話 Telephone: (852) 2300 6740

Request for Clarification on Hospital Authority (HA)'s Views on Avastin (Bevacizumab) as Safe and Efficacious Treatment for Wet AMD

Thank you for your letter of 11 June 2010 expressing your concerns over the use of Bevacizumab for treatment for wet age-related macular degeneration (AMD). However, I would like to reiterate that drug safety and patient benefits are our primary concerns in providing healthcare services for the community. As this juncture, HA has no conclusion on the use of vascular endothelial growth factor (VEGF) inhibitors as standard treatment for wet AMD. The HA is open to different treatment options and would consider the safety, efficacy and cost-effectiveness of different drugs with reference to published scientific evidence, expert advice as well as international practice in the safe use of drugs. HA will keep in view the development of scientific evidence in the field, including the findings of large-scale randomized controlled studies on various VEGF inhibitors, to consider whether individual drugs should be included into the standard treatment.

The concerns that you raised in the afore-mentioned letter are noted and will be taken into consideration at appropriate time points in our future review. Thank you for your attention.

Yours sincerely,

(Dr W L CHEUNG) for Chief Executive

/Hospital Authority

Iospital Authority Building 147B Argyle Street Kowloon, Hong Kong

傳真 Facsimile: (852) 2194 6847



c.c. Secretary for Food and Health, HKSAR

Under Secretary for Food and Health, HKSAR

Director of Health, HKSAR

Legislative Council Members

Chief Executive, Consumer Council

The Hong Kong Medical Association

The Pharmaceutical Society of Hong Kong

The Society of Hospital Pharmacists of Hong Kong

Chairman, Hospital Authority

Institution Review Board of Queen Mary Hospital, Tuen Mun Hospital and United Christian Hospital

Country Director, US Food and Drug Administration